登录新浪财经APP 搜索【信披】查看更多考评等级 （一）公司基本情况 全称：山东中创软件商用中间件股份有限公司 简称：中创股份 代码：688695.SH IPO申报日期：2022年6月29日 上市日期：2024年3月13日 上市板块：上证科创板 所属行业：软件和信息技术服务业 IPO保荐机构：开源证券、民生证券 保荐代表人：张姝、夏卡，崔增英、谢国敏 IPO承销商：开源证券、民生证券 IPO律师：国浩律师（济南）事务所 IPO审计机构：容诚会计师事务所（特殊普通合伙） （二）执业评价情况 （1）信披情况： 被要求说明招股说明书相关信息披露及股东承诺是否准确；被要求修改"技术升级及产品迭代的风 险"、"公司规模扩张带来的管理风险"等笼统泛化的表述，增强针对性和准确性；被要求说明"在国内处 于领先水平"及类似表述的具体依据；被要求进一步说明公司在取得经客户签署验收文件时确认收入的 依据是否充分；首轮问询第3.2项中，公司未回复InforSuite系列中间件产品及相关迭代产品的收入情 况，首轮问询第3.2项与第4项关于相关产品进口替代收入比例存在前后矛盾。 （2）监管处罚情况：不扣分 （7）上市首日表现 上市首日股 ...

Company Overview - Company Name: Shandong Boyuan Pharmaceutical Chemical Co., Ltd [1] - Stock Code: 301617.SZ [1] - IPO Application Date: June 17, 2022 [1] - Listing Date: December 11, 2024 [1] - Industry: Chemical Raw Materials and Chemical Products Manufacturing [1] - Underwriter: Zhongtai Securities [1] Regulatory and Performance Evaluation - Disclosure Issues: The company was required to explain the omission of sales personnel numbers and ensure the accuracy of related party disclosures [1] - Listing Cycle: The average listing cycle for A-share companies in 2024 is 629.45 days, while Boyuan's cycle is 908 days, exceeding the average [2] - Underwriting Fees: The underwriting and sponsorship fees amount to 50.9165 million yuan, with a commission rate of 7.14%, lower than the average of 7.71% [3] Market Performance - First Day Performance: The stock price increased by 188.47% on the first day of listing [4] - Three-Month Performance: The stock price rose by 98.41% compared to the issue price within three months [6] Financial Metrics - Issuance Price-Earnings Ratio: The issuance P/E ratio is 15.86 times, which is 69.59% of the industry average of 22.79 times [7] - Fundraising Amount: Expected fundraising was 753 million yuan, but the actual amount raised was 713 million yuan, a decrease of 5.13% [8] - Short-Term Performance: In 2024, the company's revenue increased by 29.53% year-on-year, and net profit attributable to shareholders grew by 17.04% [9] Overall Evaluation - Total Score: Boyuan's IPO project scored 82 points, classified as Grade B [10] - Negative Factors: Issues include the need for improved disclosure quality, a lengthy listing cycle, reduced actual fundraising, and a subscription rate of 0.23% [10]